HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA proposed OTC label reg would require "extensive" relabeling for cosmetic-drugs -- CTFA.

This article was originally published in The Rose Sheet

Executive Summary

FDA OTC DRUG LABELING REG WOULD REQUIRE "MOST EXTENSIVE" RELABELING EFFORT for the cosmetics industry in "recent memory," the Cosmetic, Fragrance and Toiletry Association said in an April 17 letter to FDA requesting a 120-day extension on the comment period for the proposed rule. The labeling reg "will affect every cosmetic-drug brand and every size of the product type sold in the United States," CTFA maintains.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel